RRMS disability progression rates have decreased over the years due to advances in disease-modifying therapies (DMTs), per an ...

It licensed the compound, an anti-CD20 mAb, to London-based GlaxoSmithKline ... Ilaris (canakinumab), an interleukin-1β inhibitor, was fully developed in-house at the Boston headquarters of ...

One rival to Imjudo/Imfinzi in previously untreated HCC is Roche's dual regimen of PD-L1 inhibitor Tecentriq (atezolizumab) and CD20-targeting antibody Avastin (bevacizumab), which was approved by ...

Also known as selective COX-2 inhibitors, these medications treat inflammatory pain. Selective COX-2 inhibitors are a type of nonsteroidal anti-inflammatory medication (also known as NSAIDs).

Evobrutinib was the first BTK inhibitor to show proof-of-concept in ... That could give the drugs an advantage over CD20-targeting therapies like Roche's Ocrevus (ocrelizumab) – which inhibit ...

ACE inhibitors are best known for treating high blood pressure. They work by targeting the hormone angiotensin II. Angiotensin-converting enzymes (ACE) inhibitors help blood vessels to relax and open.

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

In addition, some antibodies bind to different epitopes of CD20, which may yield different ... are also of interest. The mTOR inhibitor temsirolimus is active in refractory MCL, with a 38% ...

Trial-in-progress presentation provides an overview of a Phase 2 study of sonrotoclax in patients with R/R WM, who have been previously treated with a BTK inhibitor therapy or anti-CD20–based ...

On account of these limitations, he typically favors the alkylating agent bendamustine plus the anti-CD20 rituximab over BTK inhibitors in the absence of MYD88 mutations. This once standard ...